Grail shares surged 33% as FDA documents suggest a favorable view of its multi-cancer blood test

FDA documents posted ahead of a Wednesday advisory committee meeting suggest the agency may look favorably on Grail's Galleri blood test, which aims to detect multiple cancers early. Grail's shares rose 33% Monday. The test is already sold as a lab diagnostic; FDA approval would open the door to Medicare and insurer reimbursement.